(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Niven Mehra presented an exploratory ad hoc biomarker analyses assessing non-DDR/HRR mutational landscape and associations with antitumor activity among patients treated with talazoparib for metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-1 trial (NCT03148795).